302 related articles for article (PubMed ID: 23711419)
1. Fasting and post-prandial glucose and diabetic complication. A meta-analysis.
Monami M; Adalsteinsson JE; Desideri CM; Ragghianti B; Dicembrini I; Mannucci E
Nutr Metab Cardiovasc Dis; 2013 Jul; 23(7):591-8. PubMed ID: 23711419
[TBL] [Abstract][Full Text] [Related]
2. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials.
Mannucci E; Monami M; Lamanna C; Gori F; Marchionni N
Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):604-12. PubMed ID: 19427768
[TBL] [Abstract][Full Text] [Related]
3. Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer.
Holden SE; Jenkins-Jones S; Morgan CL; Schernthaner G; Currie CJ
Diabetes Obes Metab; 2015 Apr; 17(4):350-62. PubMed ID: 25399739
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Safety of Current and Emerging Glucose-Lowering Therapies.
Fitchett D
Can J Diabetes; 2015 Dec; 39 Suppl 5():S176-82. PubMed ID: 26654861
[No Abstract] [Full Text] [Related]
5. The Role of Hypoglycemia in Cardiovascular Outcomes in Diabetes.
Paty BW
Can J Diabetes; 2015 Dec; 39 Suppl 5():S155-9. PubMed ID: 26654859
[TBL] [Abstract][Full Text] [Related]
6. A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus.
Owens DR; Monnier L; Hanefeld M
Diabetes Obes Metab; 2017 Dec; 19(12):1645-1654. PubMed ID: 28474401
[TBL] [Abstract][Full Text] [Related]
7. Estimates of the relative and absolute diurnal contributions of fasting and post-prandial plasma glucose over a range of hyperglycaemia in type 2 diabetes.
Peter R; Dunseath G; Luzio SD; Owens DR
Diabetes Metab; 2013 Sep; 39(4):337-42. PubMed ID: 23993831
[TBL] [Abstract][Full Text] [Related]
8. Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: A perspective on glucose-lowering interventions.
Roussel R; Steg PG; Mohammedi K; Marre M; Potier L
Diabetes Obes Metab; 2018 Feb; 20(2):238-244. PubMed ID: 28597588
[TBL] [Abstract][Full Text] [Related]
9. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials.
Lamanna C; Monami M; Marchionni N; Mannucci E
Diabetes Obes Metab; 2011 Mar; 13(3):221-8. PubMed ID: 21205121
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data.
Gourgari E; Wilhelm EE; Hassanzadeh H; Aroda VR; Shoulson I
J Diabetes Complications; 2017 Dec; 31(12):1719-1727. PubMed ID: 28939018
[TBL] [Abstract][Full Text] [Related]
11. Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives.
Bonora E
Int J Clin Pract Suppl; 2002 Jul; (129):5-11. PubMed ID: 12166607
[TBL] [Abstract][Full Text] [Related]
12. Results of ACCORDIAN in ACCORD with lower blood pressure begetting lower mortality in patients with diabetes.
Laffin LJ; Bakris GL
Diabetes Obes Metab; 2018 Jun; 20(6):1335-1336. PubMed ID: 29424470
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials.
Monami M; Genovese S; Mannucci E
Diabetes Obes Metab; 2013 Oct; 15(10):938-53. PubMed ID: 23594109
[TBL] [Abstract][Full Text] [Related]
14. Effect of intensive glycemic control on cardiovascular outcomes and all-cause mortality in type 2 diabetes: Overview and metaanalysis of five trials.
Tkác I
Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S57-62. PubMed ID: 20115934
[TBL] [Abstract][Full Text] [Related]
15. Poststroke glycemic variability increased recurrent cardiovascular events in diabetic patients.
Yoon JE; Sunwoo JS; Kim JS; Roh H; Ahn MY; Woo HY; Lee KB
J Diabetes Complications; 2017 Feb; 31(2):390-394. PubMed ID: 27956053
[TBL] [Abstract][Full Text] [Related]
16. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: a meta-analysis.
Zhang CY; Sun AJ; Zhang SN; Wu CN; Fu MQ; Xia G; Wang KQ; Zou YZ; Ge JB
Ann Med; 2010 May; 42(4):305-15. PubMed ID: 20429797
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective.
Fisher M
Diabetes Obes Metab; 2015 Apr; 17(4):335-42. PubMed ID: 25155010
[TBL] [Abstract][Full Text] [Related]
18. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).
Basile JN
J Diabetes Complications; 2013; 27(3):280-6. PubMed ID: 23375850
[TBL] [Abstract][Full Text] [Related]
19. [Blood pressure control in patients with diabetes mellitus. Focus on postprandial blood glucose values and cardiovascular risk].
MMW Fortschr Med; 2012 Feb; 154(3):82-3. PubMed ID: 22458177
[No Abstract] [Full Text] [Related]
20. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials.
Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
Diabetes Obes Metab; 2014 Jan; 16(1):38-47. PubMed ID: 23829656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
